Document:

Exhibit
10.1

AGREEMENT BY AND BETWEEN ZANDER
THERAPEUTICS INC. AND JUDITH A VARNER

Agreement made on April 24th, 2019 (“Execution Date”) by and between
Judith A Varner (“Scientific Advisory Board Member” also referred to as “SAB Member”), a natural person
whose address is at ________________________________ and Zander Therapeutics Inc. (“Company”), a Nevada corporation
whose address is 4700 Spring Street, St 304, La Mesa, California 91942. SAB Member and Company may be referred to individually
as “Party” and collectively as “Parties”.

 

It is agreed as follows:

1.     
SCOPE OF SERVICES

SAB
Member shall advise client on various nominal matters regarding veterinary biotechnology for the Company, Zander Therapeutics
Inc. "Nominal" is defined as periodic conversations in which SAB Member is asked for a referral to an appropriate researcher
on a specific topic or input on research data the company is developing. In the event SAB Member is requested to provide research
services, such services will be negotiated separately between SAB Member and the Company.

2.     
TERM

The
Term of this Agreement shall commence on April 24, 2019 and shall expire on April 23, 2020. The term of this Agreement may be
extended by mutual agreement.

3.     
INDEPENDENT CONTRACTOR

The
Parties are independent contractors. Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between
the Parties or constitute any Party to be the agent of the other Party for any purpose.

4.     
NON-DISCLOSURE

	(a)	 	All
    information, whether in oral, written, graphic, electronic or other form, disclosed by the Company to the SAB Member shall
    be deemed to be “Proprietary Information.” In particular, Proprietary Information includes, without limitation,
    any trade secrets, confidential information, ideas, inventions or research and development information; matters of a technical
    nature, including technology; notes, products, know-how, engineering or other data (including test data and data files); specifications,
    processes, techniques, formulae or work-in-process; manufacturing, planning or marketing procedures, clinical data and regulatory
    strategies or information; accounting, financial or pricing procedures or information, budgets or projections, or personnel
    or salary structure/compensation information; information regarding suppliers, clients, customers, employees, contractors,
    investors or investigators of the Company, information which has been designated in writing as confidential by the Company;
    programs, procedures (including operating procedures), processes, methods, guidelines, policies, proposals or contracts; computer
    software, data bases or programming; and any other information which, if divulged to a third party, could have an adverse
    impact on the Company, or on any third party to which it owes a confidentiality obligation. In addition, “Proprietary
    Information” includes any of the foregoing relating to the past, present or future operations, organization, projects,
    finances, business interests, methodology or affairs of any third party to which the Company owes a duty of confidentiality
    including, without limitation, the mere fact that the Company is or may be working with or for any client.

 

	(b)	 	The
    obligations of confidentiality shall not apply to any Proprietary Information that was known by the SAB Member at the time
    of disclosure to it by such Company, or that is independently developed or discovered by the SAB Member after disclosure by
    such Company, without the aid, application or use of any item of such Company’s Proprietary Information, as evidenced
    by written records; now, or subsequently becomes, through no act or failure to act on the part of the SAB Member, generally
    known or available; is disclosed to the SAB Member by a third party authorized to disclose it; or is required by law or by
    court or administrative order to be disclosed; provided, that the SAB Member shall have first given prompt notice to such
    Company of such required disclosure.

 

	(c)	 	SAB
    Member shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
    and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
    any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
    or agents of the SAB Member (collectively, “Representatives”), to the extent such Representatives reasonably need
    to know the same in order to evaluate such Proprietary Information, to participate in the business relationship between the
    parties, or to make decisions or render advice in connection therewith. SAB Member shall advise its Representatives who have
    access to the Company’s Proprietary Information of the confidential and proprietary nature thereof, and agrees that
    such Representatives shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least
    as restrictive as the terms of this Agreement.

 

	(d)	 	SAB
    Member shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
    and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
    any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
    or agents of the SAB Member (collectively, “Representatives”), to the extent such Representatives reasonably need
    to know the same in order to participate in any business relationship between the parties, or to make decisions or render
    advice in connection therewith. SAB Member shall advise its Representatives who have access to the Company’s Proprietary
    Information of the confidential and proprietary nature thereof, and agrees that such Representatives shall be bound by terms
    of confidentiality and restrictions on use with respect thereto that are at least as restrictive as the terms of this Agreement.

 

	(e)	 	SAB
    Member shall use the Company’s Proprietary Information solely for the purposes of performing his duties pursuant to
    this Agreement and shall not make any other use of the Company’s Proprietary Information without the Company’s
    specific written authorization.

 

	(f)	 	All
    Proprietary Information of the Company (including all copies thereof) shall be and at all times remain the property of such
    Company, and all non-oral Proprietary Information of the Company which is then in the SAB Member’s possession or control
    shall be destroyed or returned to the Company promptly upon its request at any time, and in any event, no later than 60 days
    following any expiration or termination of this Agreement.

 

	(g)	 	Nothing
    in this Agreement shall be construed, by implication or otherwise, as a grant of any right or license to trademarks, inventions,
    copyrights or patents, as a grant of a license to either SAB Member to use any of the Company’s Proprietary Information
    except as expressly set forth herein.

 

	(h)	 	The
    provisions of Section 4 of this Agreement shall survive until such time as all Confidential Information disclosed hereafter
    becomes publically known and made generally available through no action or inaction of SAB Member.

 

5.
CONSIDERATION  

 

As
consideration of the performance of services pursuant to this Agreement, SAB Member shall receive:

 

(1)   
Within 15 business days of the execution date of this Agreement SAB Member shall be issued 100,000 shares of the Zander Therapeutics
Inc.'s Series M Preferred Stock of the Company (“Compensation Shares”).

 

(2)   
SAB Member acknowledges that, in the event that a Zander Registration Statement is filed with the United States Securities and
Exchange Commission (“SEC”), no assurance is given that the Zander Registration Statement will be declared effective
by the SEC.

 

(3)   
SAB Member acknowledges that any securities issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

6.     
REPRESENTATIONS AND WARRANTIES OF COMPANY

	(a)	 	Company
    is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has
    the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained.

 

	(b)	 	The
    execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the Company is a party, or by which Company is or may be bound.

 

7.     
REPRESENTATIONS AND WARRANTIES OF SAB MEMBER

	(a)	 	SAB
    Member has the requisite power and authority to enter into and perform his obligations under this Agreement without the consent,
    approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been
    obtained.

 

	(b)	 	The
    execution, delivery and performance of this Agreement by SAB Member does not and shall not constitute SAB Member’s breach
    of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach
    of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement,
    or instrument to which the SAB Member is a party, or by which Company is or may be bound.

 

8.     
NON-DISPARAGEMENT

SAB
Member agrees that SAB Member shall not, during the term of this Agreement, disparage the Company, the Company’s products,
the Company’s employees, or members of the Company’s board of directors. For purposes of this Agreement the term “disparage”
shall mean any negative comment, written or oral, about the Company, the Company’s products, the Company’s employees,
or members of the Company’s board of directors. . Nothing set forth in this Agreement shall prohibit or limit in any way
a Party’s right to accurately and honestly respond as required or to cooperate with any valid government, court or regulatory
order or request. The provisions of Section 8 of this Agreement shall survive until that date which is three years subsequent
to the end of the Term of this Agreement.

9.     
WORK PRODUCT

SAB
Member agrees that the Company is the sole and exclusive owner of all intellectual property, including copyrights, trademarks,
patents, inventions, work product and know-how, which may result from any work performed by the SAB Member pursuant to this Agreement.
SAB Member agrees that SAB Member shall, upon request of the Company, execute, acknowledge, deliver and file any and all documents
necessary or useful to vest in the Company all of SAB Member’s right, title and interest in and to all intellectual property,
including copyrights, trademarks, patents, inventions, work product and know-how, which may result from any work performed by
the SAB Member pursuant to this Agreement. The term "Inventions" means all original works of authorship, developments,
concepts, improvements or trade secrets, whether or not patentable under law, that SAB Member may individually or jointly conceive
or develop or reduce to practice, or cause to be conceived or developed or reduced to practice.

10.     
SPECIFIC PERFORMANCE

Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available, SAB Member acknowledges and agrees that Company may immediately
seek enforcement of this Agreement by means of specific performance or injunction, without any requirement to post a bond or other
security.

11. 
EXECUTION

This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

12. 
ENTIRE AGREEMENT

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

13. 
SEVERABILITY

If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement

14.
GOVERNING LAW, VENUE, WAIVER OF JURY TRIAL

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

    	 	1	 

     

    

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

	COMPANY	 	SAB
    MEMBER
	By:
    David R. Koos, PhD	 	By:
    
	/s/David
    Koos	 	/s/Judith
    Varner
	Its:
    Chairman & CEO	 	 
	Date:
    	 	Date:
    April 24, 2019

 

    	 	2grvy-ex41_176.htm

Exhibit 4.1

9th AMENDMENT

TO THE 2nd RENEWAL OF RAGNAROK LICENSE AND DISTRIBUTION AGREEMENT

 

THIS AMENDMENT (“Amendment”) is made and entered into on this 29th day September, 2017 (“Effective Date”) by and between Gravity Co., Ltd., a corporation duly organized and existing under the laws of the Republic of Korea (hereinafter referred to as “Korea”) and having its principle office at 15F Nuritkum Square R&D Tower, Worldcup Bukro 396, Mapo-Gu, Seoul, 03925, Korea (“Licensor”) and GungHo Online Entertainment, Inc., a corporation duly organized and existing under the laws of Japan and having its principal office at 1-11-1 Marunouchi, Chiyoda-ku, Tokyo, 100-6221 Japan (“Licensee”). 

 

WHEREAS, Licensor and Licensee (“Parties”) entered into the 2nd Renewal of Ragnarok License and Distribution Agreement dated September 29, 2006 (“Original Agreement”).

 

WHEREAS, the Parties entered into the several Amendments (“Prior Amendments”) listed in the table below. Each amendment shall be hereinafter referred to such name as defined in the Note of the table below.

 

			
	
Title
	
Signed Date
	
Note

	
Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
Dec. 17, 2007
	
1st AMENDMENT

	
Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
Sep. 9, 2008
	
2nd AMENDMENT

	
Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
Sep. 29, 2009
	
3rd AMENDMENT

	
Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
Nov. 1, 2009
	
4th AMENDMENT

	
2nd Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
May. 31, 2010
	
5th AMENDMENT

	
Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement
	
Aug. 23, 2011
	
6th AMENDMENT

	
7th AMENDMENT TO THE 2nd RENEWAL OF RAGNAROK LICENSE AND DISTRIBUTION AGREEMENT
	
Sep 29, 2012
	
7th AMENDMENT

	
8th Amendment to the 2nd Renewal of Ragnarok License and Distribution Agreement 
	
Sep 29, 2015
	
8th AMENDMENT

 

 

WHEREAS, the Parties hereto desires to amend the Original Agreement amended by Prior Amendments (hereinafter referred to as “The Agreement”) as specified below. 

 

NOW, THEREFORE, in consideration of the mutual premises and covenants contained herein, Licensor and Licensee agree as follows:

 

1

 

	
1.
	
Renewal Term

The Parties agree to extend the term of The Agreement for two (2) years (“Renewed Term”) from September 29, 2017 with conditions stated below in this Amendment. The newly extended term of The Agreement shall be from September 29, 2017 to September 28, 2019 without any License Fee.

 

	
2.
	
Royalty Payment 

Licensee shall pay to Licensor as Royalty Payments Forty percent (40%) of the Net Revenue during the Renewed Term. All other Royalty Payment and Report conditions shall remain the same as set out in The Agreement.

 

	
3.
	
Technical Support
During the Renewed Term, Licensor shall make commercially reasonable efforts to provide the same level of technical support for the Game as that provided by Licensor to Licensee during the preceding Renewed Term set forth in the 8th AMENDMENT (from September 29, 2015 to September 28, 2017).

 

	
4.
	
Continuing Effectiveness of the Original Agreement
Except as expressly set forth herein, this Amendment shall not by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in The Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect.

 

	
5.
	
Effective Date
All the Articles of The Agreement amended by this Amendment shall be effective and applicable on and from Effective Date of this Amendment as said above.

 

IN WITNESS WHEREOF, the Parties have caused their respective representatives to execute this Amendment in duplicate and each party retains one copy.

 

 

					
	
GRAVITY Co., Ltd.
	
GungHo Online Entertainment, Inc.

	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
 
	
By:
	
 

	
Name:
	
Hyun Chul Park
	
 
	
Name:
	
Kazuki Morishita

	
Title:
	
CEO
	
 
	
Title:
	
President & CFO

 

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]